RayStation Chosen For Several New Proton Therapy Centers in Japan
News Jul 28, 2016
RayStation® has been selected as the treatment planning solution for several new proton therapy centers in Japan. The centers will deliver radiation treatments using Mitsubishi Electric's proton therapy system. Mitsubishi Electric chose the RayStation system, which is marketed in Japan by Hitachi, Ltd. ("Hitachi").
The order followed an evaluation of the treatment planning system provided by RaySearch, and also of the customer support provided by Hitachi. The system includes Pencil Beam Scanning (PBS) and Uniform Scanning (US), and these will be the first clinical installations of RayStation for proton therapy in Japan.
Proton therapy is an important area of focus for RaySearch. Outstanding capabilities for proton planning, based on proven, innovative technology, make RayStation the treatment planning solution of choice for many of the leading proton therapy centers worldwide. RayStation has been selected by centers with proton systems from all the leading suppliers, including IBA, Varian, Mevion, Mitsubishi and Sumitomo.
Johan Löf, CEO of RaySearch Laboratories, says: "I am delighted to be taking proton therapy forward in Japan, together with Hitachi and Mitsubishi Electric. Mitsubishi has a large installed base of proton therapy systems in Japan, and together we have an opportunity to take clinical excellence to new levels."
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
Insulin Goes Viral: Diabetes and Cancer-causing Mechanisms ExploredNews
Every cell in your body responds to the hormone insulin, and if that process starts to fail, you get diabetes. In an unexpected finding, scientists have identified four viruses that can produce insulin-like hormones that are active on human cells. The discovery brings new possibilities for revealing biological mechanisms that may cause diabetes or cancer.READ MORE
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018